MEDVi vs Synergy Rx
One seller publishes a figure for a single line; the other prices all four.
Disclosure: Buy This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
MEDVi
Editorial
$249/mo
One line priced as a price and two priced as a membership. Compounded semaglutide by injection is a flat $249 with no introductory discount shown, while the oral semaglutide and tirzepatide lines publish $99 as a membership fee and state the medication cost separately without naming it. Coverage is stated across 48 states.
Pick it for: Buyers who only want the injection and nothing else priced
Synergy Rx
Partner
$199/mo
Four rates published, not two: semaglutide $199 injectable and $299 oral, tirzepatide $349 injectable and $399 oral. Most sellers quote the injection and make you fill in a form to learn the oral. Fifty states.
Pick it for: Buyers who want to compare formats before handing over details
Our verdict
MEDVi publishes a figure for its injection only; its other lines quote a membership and leave the drug cost unstated. Synergy Rx prices all four combinations outright.
What actually separates them
MEDVi and Synergy Rx state different things about published price and where you can use it. Everything else they publish, they publish the same way.
MEDVi costs $50 more than Synergy Rx — 25% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $2,388 at Synergy Rx against $2,988 at MEDVi — a difference of $600.
| MEDVi | Synergy Rx | |
|---|---|---|
| Published price | $249/mo | $199/mo |
| Where you can use it | 48 states | 50 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.